Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
found
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
The bankruptcy of genealogy company 23andMe has resulted in a fire sale of millions of people’s genetic information – and there’s no shortage of eager buyers with questionable motives
Ever thought of …